These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9647246)

  • 1. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.
    Roberts MR; Cooke KS; Tran AC; Smith KA; Lin WY; Wang M; Dull TJ; Farson D; Zsebo KM; Finer MH
    J Immunol; 1998 Jul; 161(1):375-84. PubMed ID: 9647246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes.
    Tran AC; Zhang D; Byrn R; Roberts MR
    J Immunol; 1995 Jul; 155(2):1000-9. PubMed ID: 7608531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
    Moritz D; Groner B
    Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc epsilonRI gamma can support T cell development and function in mice lacking endogenous TCR zeta-chain.
    Shores E; Flamand V; Tran T; Grinberg A; Kinet JP; Love PE
    J Immunol; 1997 Jul; 159(1):222-30. PubMed ID: 9200458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCR-gamma delta cells in CD3 zeta-deficient mice contain Fc epsilon RI gamma in the receptor complex but are specifically unresponsive to antigen.
    Khattri R; Sperling AI; Qian D; Fitch FW; Shores EW; Love PE; Bluestone JA
    J Immunol; 1996 Sep; 157(6):2320-7. PubMed ID: 8805629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
    Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ; Darcy PK
    J Immunol; 2001 Jan; 166(1):182-7. PubMed ID: 11123291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.
    Finney HM; Lawson AD; Bebbington CR; Weir AN
    J Immunol; 1998 Sep; 161(6):2791-7. PubMed ID: 9743337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.
    Turatti F; Figini M; Balladore E; Alberti P; Casalini P; Marks JD; Canevari S; Mezzanzanica D
    J Immunother; 2007 Oct; 30(7):684-93. PubMed ID: 17893561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the zeta protein subunit in CD3- NK effectors derived from human thymus.
    Beecher MS; Baiocchi RA; Linett ML; Krajewski CA; Caligiuri MA
    Cell Immunol; 1994 May; 155(2):508-16. PubMed ID: 7514106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A chimeric T cell receptor with super-signaling properties.
    Petersen TR; Gülland S; Bettelli E; Kuchroo V; Palmer E; Bäckström BT
    Int Immunol; 2004 Jul; 16(7):889-94. PubMed ID: 15148288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental dissociation of T cells from B, NK, and myeloid cells revealed by MHC class II-specific chimeric immune receptors bearing TCR-zeta or FcR-gamma chain signaling domains.
    Lin WY; Roberts MR
    Blood; 2002 Oct; 100(8):3045-8. PubMed ID: 12351421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective binding of shc-SH2 domain to tyrosine-phosphorylated zeta but not gamma-chain upon CD16 ligation on human NK cells.
    Galandrini R; Palmieri G; Paolini R; Piccoli M; Frati L; Santoni A
    J Immunol; 1997 Oct; 159(8):3767-73. PubMed ID: 9378963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T lymphocyte development in the absence of CD3 epsilon or CD3 gamma delta epsilon zeta.
    Wang B; Wang N; Whitehurst CE; She J; Chen J; Terhorst C
    J Immunol; 1999 Jan; 162(1):88-94. PubMed ID: 9886373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes.
    Geiger TL; Leitenberg D; Flavell RA
    J Immunol; 1999 May; 162(10):5931-9. PubMed ID: 10229830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
    Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
    Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors.
    Patel SD; Moskalenko M; Tian T; Smith D; McGuinness R; Chen L; Winslow GA; Kashmiri S; Schlom J; Stanners CP; Finer MH; McArthur JG
    Cancer Gene Ther; 2000 Aug; 7(8):1127-34. PubMed ID: 10975673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential development of structural and functional alterations in T cells from tumor-bearing mice.
    Correa MR; Ochoa AC; Ghosh P; Mizoguchi H; Harvey L; Longo DL
    J Immunol; 1997 Jun; 158(11):5292-6. PubMed ID: 9164948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.